Tak 677;AJ-9677;AD-9677

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Tak 677;AJ-9677;AD-9677
• 英文别名: 2-[[3-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1H-indol-7-yl]oxy]acetic acid
• 化学式: C₂₁H₂₃ClN₂O₄
• 分子量: 402.9
• InChiKey: FHEYFIGWYQJVDR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  28
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  94.6
• 氢给体数：
  4
• 氢受体数：
  5

文献信息

• INDOLE DERIVATIVE
  申请人：DAINIPPON PHARMACEUTICAL CO., LTD.

  公开号：EP0801059A1

  公开（公告）日：1997-10-15

  An indole derivative of the formula: wherein R1 is lower alkoxy, lower alkoxycarbonyl-lower alkoxy, carboxy-lower alkoxy , lower alkoxycarbonyl, phenyl-lower alkoxy, lower alkyl being optionally substituted by hydroxy, di-lower alkylaminosulfonyl, etc., R2 is hydrogen, halogen, lower alkoxy, lower alkoxycarbonyl-lower alkoxy, carboxy-lower alkoxy, etc., R3 is hydrogen or lower alkyl, R4 is halogen or trifluoromethyl, R5 is lower alkyl, or a salt thereof, these compounds being potent β3-adrenergic receptor-stimulating agent with excellent adrenoceptor selectivity, and being useful in the prophylaxis or treatment of obesity or diabetes mellitus.

  一种吲哚衍生物，其式如下 其中 R1 是低级烷氧基、低级烷氧羰基-低级烷氧基、羧基-低级烷氧基、低级烷氧羰基、苯基-低级烷氧基、任选被羟基取代的低级烷基、二低级烷基氨基磺酰基等，R2 是氢、卤素、低级烷氧基、低级烷氧羰基-低级烷氧基、羧基-低级烷氧基等、R3是氢或低级烷基，R4是卤素或三氟甲基，R5是低级烷基，或其盐，这些化合物是强效的β3-肾上腺素能受体刺激剂，具有良好的肾上腺素受体选择性，可用于预防或治疗肥胖症或糖尿病。
• Combinations comprising a beta-agonist and a further antidiabetic agent
  申请人：SmithKline Beecham p.l.c.

  公开号：US20030073644A1

  公开（公告）日：2003-04-17

  A method for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal such as a human, which method comprises administering an effective, non-toxic and pharmaceutically acceptable amount of a beta agonist and another antidiabetic agent, to a mammal in need thereof.

  一种治疗哺乳动物（如人类）糖尿病及糖尿病相关病症的方法，该方法包括向有需要的哺乳动物施用有效、无毒且药学上可接受量的β受体激动剂和另一种抗糖尿病剂。
• Compositions and methods for the amelioration of leptin resistance
  申请人：——

  公开号：US20040242485A1

  公开（公告）日：2004-12-02

  It is an objective of the present invention to provide a novel method of ameliorating leptin resistance. In order to achieve the above objective, the present invention provides a method of ameliorating leptin resistance in a patient, which comprises a process of administering a &bgr; 3 adrenergic receptor agonist to the patient with leptin resistance.

  本发明的目的是提供一种改善瘦素抵抗的新方法。为了实现上述目标，本发明提供了一种改善患者瘦素抗性的方法，该方法包括给患者注射一种&bgr； 3 肾上腺素能受体激动剂。
• COMBINATIONS COMPRISING A BETA-AGONIST AND A FURTHER ANTDIABETIC AGENT
  申请人：SMITHKLINE BEECHAM PLC

  公开号：EP1128845A1

  公开（公告）日：2001-09-05
• AMINOALCOHOL DERIVATIVES USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP1230210A1

  公开（公告）日：2002-08-14